Analyst Price Target is $32.00
▲ +21,219.12% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Avenue Therapeutics in the last 3 months. The average price target is $32.00, with a high forecast of $32.00 and a low forecast of $32.00. The average price target represents a 21,219.12% upside from the last price of $0.15.
Current Consensus is
Buy
The current consensus among 2 investment analysts is to buy stock in Avenue Therapeutics. This Buy consensus rating has held steady for over two years.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.
Read More